a.lindholm

TL2 · Split

Contributes reviews on supplier material. Based in Split.

Joined 21 November 2024 · last posted 3d · groups: translators

79 posts, newest first. Showing up to 150.

Common supplements people ask about, assessed one at a time Replied, post #97 · Practice › Interactions · 25 Jul 2026 · 16 likes Practical answer on common supplements, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide whether the…
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one Replied, post #25 · Compounds › Oral incretins · 25 Jul 2026 · 0 likes Post #24 put the caveat in the right place and I want to underline it. Orforglipron is a small molecule rather than a peptide, which changes almost everything about how…
Distinguishing a red flag from an inconvenience — a second dataset Replied, post #9 · Sourcing › Red flags · 24 Jul 2026 · 4 likes Taking post #6 at face value and following it one step further. The most useful contribution to this subcategory is a resolved case written up with the resolution,…
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #100 · Evidence › Journal club · 22 Jul 2026 · 1 like The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to. The general…
Seven-day rolling means and why weekly readings mislead Replied, post #71 · Outcomes › Progress reports · 20 Jul 2026 · 1 like State the method before the numbers. Same scale, same time of day, same conditions — without that a series is a collection of readings rather than a measurement. I have…
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #64 · Analytics › Home & field testing · 8 Jul 2026 · 31 likes Building on post #61 rather than restating it. Where I have landed on consumer-accessible tests, having got it wrong once in public: the direction is clear, the…
Semaglutide formulation: what is in the licensed product besides the peptide Replied, post #26 · Compounds › Semaglutide · 2 Jul 2026 · 7 likes Sensible. I would want the same detail before I acted on it either.
Prescription requirements and telehealth models — a second dataset Replied, post #79 · Sourcing › Regulatory · 25 Jun 2026 · 1 like Prescription requirements and telehealth models has been discussed here with more heat than it deserves, mostly because two definitions have been in play the whole time.
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Replied, post #10 · Compounds › Retatrutide · 21 Jun 2026 · 13 likes Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is mechanistically plausible for benefit in metabolic liver disease. Whether that…
Publication patterns in the BPC-157 literature, examined Replied, post #10 · Compounds › Repair & healing peptides · 9 Jun 2026 · 16 likes I read post #6 twice before replying, because I had assumed the opposite. BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a…
[2026 update] Regional warehouse stock versus direct despatch Replied, post #92 · Sourcing › Logistics · 5 Jun 2026 · 10 likes Document outcomes rather than forecasting them. A forecast in this category reads as reassurance and is not one. Where I would look next, rather than where I would stop.
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one… Replied, post #8 · Compounds › Retatrutide · 2 Jun 2026 · 5 likes Glycaemic effects improved rather than worsened in the diabetes work despite the glucagon component, which is the observation that resolves the apparent paradox. It is…
Reading a trial's population section before its results Replied, post #60 · Evidence › Trials · 27 May 2026 · 0 likes Nothing in a trial report is medical advice about an individual, and the gap between a population estimate and a person is exactly where clinical judgement lives. If…
Historical amylin analogues and what happened to them Replied, post #9 · Compounds › Cagrilintide & amylin analogues · 17 May 2026 · 22 likes Taking post #7 at face value and following it one step further. On historical amylin analogues I would separate what is worth knowing from what is worth acting on. The…
Splitting an overlong document into two Replied, post #18 · Documentation › Wiki requests · 10 May 2026 · 3 likes Suggesting content for a page: if you know a maintained page is missing something important, post a suggestion with specific content you think should be added.
Forced degradation studies: designing one that is informative Replied, post #50 · Analytics › Method validation · 6 May 2026 · 3 likes Answering the question post #46 raises rather than the one it answers. A stability-indicating method is one demonstrated to resolve the analyte from its degradation…
Why the timeline is on the right and not the left — what changed since Replied, post #28 · Meta › Site feedback · 29 Apr 2026 · 9 likes Minor and worth fixing: the printed page cuts the right rail off mid-card rather than dropping it. Anyone printing a maintained document loses the last line of the…
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #4 · Evidence › Journal club · 16 Apr 2026 · 0 likes I read the opening post twice before replying, because I had assumed the opposite. Where the group cannot agree, record the disagreement rather than resolving it by…
Prescription portability between countries Replied, post #5 · Access › International · 9 Apr 2026 · 0 likes Where I part company with post #4, and it is a narrow parting. Where I have landed on prescription portability between countries, having got it wrong once in public:…
Introducing myself: pharmacist, sceptic, reluctant participant — one year on Replied, post #23 · Lounge › Introductions · 9 Mar 2026 · 0 likes There is: the practice category, and the calculators, both written for exactly that. Nothing there assumes chemistry, and the maintained documents show their working so…
Mass error in ppm: the arithmetic and the caveat Replied, post #7 · Analytics › Mass spectrometry · 11 Feb 2026 · 29 likes No disagreement from me. Posting only so the question does not look ignored.
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #84 · Access › Pricing · 9 Feb 2026 · 19 likes Cost per milligram is the only comparison that survives format differences, but even then it needs care. A pen and a vial are not the same product and cannot be…
Waist circumference technique and its repeatability Replied, post #42 · Outcomes › Progress reports · 23 Jan 2026 · 31 likes I read the earlier replies on waist circumference technique twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with…
The most common factual error about semaglutide on the internet — what changed since Replied, post #5 · Compounds › Semaglutide · 10 Jan 2026 · 11 likes On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval…
Follow-up: A supplier that answers analytical questions with restated claims Replied, post #40 · Sourcing › Red flags · 6 Jan 2026 · 4 likes On supplier: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here…
Reading an interaction checker output critically Replied, post #78 · Practice › Interactions · 29 Dec 2025 · 32 likes Narrowing post #77, because the general version has more than one answer. Vitamins: most vitamins have no significant interaction. Fat-soluble vitamins (A, D, E, K)…
Reading SURMOUNT-1 without the press release Replied, post #79 · Compounds › Tirzepatide · 26 Nov 2025 · 7 likes SURMOUNT-4 used a randomised withdrawal design: everyone titrated, then those on maintenance were randomised to continue or placebo. Continuation maintained effect;…
[2026 update] How much of the diluent volume the powder itself displaces Replied, post #80 · Practice › Reconstitution · 26 Nov 2025 · 4 likes Grateful for the specificity. Vague answers to this question are what sent me looking.
Pharmaceutical compounding rules, summarised from primary sources — a second dataset Replied, post #46 · Sourcing › Regulatory · 24 Nov 2025 · 33 likes Post #42 describes the usual case. This is about the unusual one. Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific…
Coming back to: Injection-site reactions: describing them precisely enough to be useful Replied, post #8 · Practice › Side effects · 22 Nov 2025 · 18 likes I have no financial interest in anything named in this thread and I want to say so before I comment on Injection-site reactions, because it is the sort of subject where…
Availability by country, dated, with primary sources Replied, post #69 · Access › International · 21 Nov 2025 · 22 likes Before the thread moves on from availability — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four…
How to read a phase 2 result without treating it as a phase 3 result — what changed since Replied, post #13 · Compounds › Retatrutide · 31 Oct 2025 · 5 likes The phase 3 programme is ongoing and its results will change what can be said here. Until then, this subcategory's convention is to state the phase alongside any result…
When to stop reading forums, including this one Replied, post #40 · Wellbeing › Mental health · 23 Oct 2025 · 10 likes Helpful, and easy to find again, which is half of what a good reply is.
Second pass at: How to ask a question when you cannot say why you are asking it Replied, post #23 · Start Here › How to Ask · 15 Oct 2025 · 4 likes Answering the question post #19 raises rather than the one it answers. It is fine to say you cannot explain why you are asking. Nobody will press, and the technical…
Payment method and the leverage it gives you, ranked Replied, post #67 · Sourcing › Payments · 24 Sep 2025 · 10 likes Taking post #66 at face value and following it one step further. Chargeback reality: if you pay by credit card and the supplier does not deliver, you can attempt a…
Can a home kit substitute for a laboratory report? A careful no Replied, post #16 · Analytics › Home & field testing · 22 Sep 2025 · 25 likes This follows post #14 rather than contradicting it. Quantitation at home is the part that does not survive scrutiny. Precision adequate to distinguish 96 from 98 per…
Why catalogue breadth is not evidence of anything — what changed since Replied, post #40 · Compounds › Other compounds · 9 Sep 2025 · 0 likes Picking up post #37: that is the part I would want checked first. Research use only, not approved for human use, and in this subcategory the compounds vary enormously…
Aggregated purity results across four services, with caveats — a second dataset Replied, post #54 · Data & Tools › Datasets · 8 Sep 2025 · 12 likes Where I part company with post #51, and it is a narrow parting. Reframing Aggregated purity results across four slightly, because I think the disagreement is about the…
[2026 update] What we do not know about retatrutide, listed explicitly Replied, post #80 · Compounds › Retatrutide · 5 Sep 2025 · 0 likes Adding the measurement that post #79 says would settle it. Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not…
Confounding by indication, explained with a concrete example Replied, post #6 · Evidence › Study critique · 31 Aug 2025 · 0 likes Where I part company with post #4, and it is a narrow parting. Attrition is the failure mode most likely to invalidate a result and the least likely to be discussed.…
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question Replied, post #40 · Evidence › Journal club · 23 Aug 2025 · 2 likes Careful with the language on orforglipron phase 2. "Not detected" and "not present" are different findings and the first is a statement about the method.
What published stability data actually covers, and what it does not — what changed since Started this topic · Practice › Storage & stability · 16 Aug 2025 · 6 likes What published stability data actually covers, and what it does not — what changed since — that is the question, and I have not found it answered plainly anywhere I…
How to research a compound with no human data without deceiving yourself Replied, post #60 · Compounds › Other compounds · 2 Aug 2025 · 6 likes Confirming post #59 from a second method, which matters more than confirming it from a second person. Summarising the research a compound thread so far, since it is…
The CagriSema phase 2 paper and what a fixed combination buys Replied, post #76 · Compounds › Cagrilintide & amylin analogues · 30 Jul 2025 · 18 likes Taking cagrisema phase 2 paper seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison,…
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Replied, post #64 · Evidence › Journal club · 4 Jul 2025 · 31 likes What I can speak to on SURMOUNT-4 and continuation versus withdrawal is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not…
Gauge and length selection for subcutaneous injection Replied, post #6 · marked as the solution · Devices › Syringes & needles · 20 Jun 2025 · 15 likes Sharps containers are a legal requirement for disposal in several jurisdictions and a sensible precaution everywhere. A rigid sealed container is the minimum. Noting…
Follow-up: Why the titration planner refuses to produce a schedule below a floor Replied, post #29 · Data & Tools › Calculators · 19 Jun 2025 · 26 likes Answering the question post #27 raises rather than the one it answers. Rounding behaviour is where two tools disagree. One rounding to the nearest graduation and one to…
Second pass at: Reading a combination trial: attributing effect to components Replied, post #26 · Compounds › Cagrilintide & amylin analogues · 10 Jun 2025 · 9 likes Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The…
Follow-up: The decimal-point error, and the habit that catches it Replied, post #6 · Practice › Reconstitution · 31 May 2025 · 0 likes Post #4 put the caveat in the right place and I want to underline it. Reading back through the decimal-point error threads from last year, the same three questions come…
Half-life, steady state, and accumulation worked through Replied, post #35 · Pharmacology › Pharmacokinetics · 28 May 2025 · 0 likes The arithmetic in post #32 is right; the assumption feeding it is the part to check. My position on half-life is current rather than settled. I have revised it once…
Follow-up: Documentation that appears only after payment Replied, post #76 · Sourcing › Red flags · 14 May 2025 · 1 like The arithmetic in post #75 is right; the assumption feeding it is the part to check. I keep a log for Documentation specifically because my memory of it turned out to…
Cost per milligram, computed honestly across formats — the long version Replied, post #91 · Access › Pricing · 7 May 2025 · 5 likes Nothing here is financial advice and none of it is a route to a transaction. A qualification I should have led with rather than closed on.
Carryover and the ghost peak from last week's standard Replied, post #88 · Analytics › HPLC & UHPLC · 12 Apr 2025 · 4 likes The bit of carryover that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread will…
Carryover and the ghost peak from last week's standard Replied, post #63 · Analytics › HPLC & UHPLC · 9 Apr 2025 · 5 likes I think the carryover question is answerable and has not been answered, which is a more optimistic position than most of this thread.
Follow-up: What other technical communities get right that we do not Replied, post #54 · Lounge › Off topic · 31 Mar 2025 · 14 likes Something I have wondered without ever asking: is there a good reason the vocabulary in this field is so inconsistent between suppliers? Half the disagreements here…
Reconstituting a multi-strength kit without mixing yourself up Replied, post #49 · Practice › Reconstitution · 26 Mar 2025 · 21 likes Preservative effectiveness is tested against a defined microbial challenge under defined conditions. It is not a licence to treat an entered vial as sterile…
What SELECT changed about how semaglutide is discussed, and what it did not Replied, post #46 · Compounds › Semaglutide · 20 Mar 2025 · 0 likes Coming back to post #44, because the follow-up matters more than the original answer. Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight…
Maintainer handover: how it works Replied, post #34 · Meta › Wiki maintenance · 15 Mar 2025 · 1 like Post #31 is right about the mechanism and I think understates the practical bit. Careful with that. A short duplicated paragraph is sometimes better than a link,…
Checking someone else's arithmetic: a worked example thread Replied, post #28 · Practice › Reconstitution · 10 Mar 2025 · 20 likes Preservative effectiveness is tested against a defined microbial challenge under defined conditions. It is not a licence to treat an entered vial as sterile…
Second pass at: Regression to the mean in progress reports Replied, post #66 · Research Methods › Statistics · 24 Feb 2025 · 3 likes Two sentences on Regression and then I will stop, because the rest is speculation and the thread is better without mine. What is documented is narrow. What is inferred…
When to suspect the method rather than the sample Replied, post #87 · Analytics › Method validation · 24 Feb 2025 · 6 likes Taking post #85 at face value and following it one step further. Precision and repeatability: within-run and between-run variability of the method. Acceptance criterion…
A page that has drifted out of date and needs a maintainer Replied, post #66 · Documentation › Wiki requests · 19 Feb 2025 · 8 likes That matches what I have seen, for whatever a single anecdote is worth.
Protein density versus volume when you cannot eat much Replied, post #25 · Nutrition & Training › Protein & intake · 27 Jan 2025 · 31 likes Protein density versus volume is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.
The topic list is dense — is that deliberate? Replied, post #85 · Meta › Site feedback · 19 Jan 2025 · 5 likes Reading back through the topic list threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems…
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how… Replied, post #4 · Compounds › Tirzepatide · 16 Jan 2025 · 6 likes Post #3 is right about the mechanism and I think understates the practical bit. The five maintenance doses in the tirzepatide programme give a genuine dose-response…
Second pass at: Triple agonism: additive, synergistic, or neither? Replied, post #2 · Compounds › Retatrutide · 30 Dec 2024 · 26 likes Coming back to the opening post, because the follow-up matters more than the original answer. One more thing on Triple agonism that took me far too long to see: the two…
[2026 update] Step therapy requirements and how to satisfy them Replied, post #93 · Access › Insurance & coverage · 29 Dec 2024 · 30 likes Post #90 is the version of this I will quote in future. One addition. My position on Step therapy requirements is current rather than settled. I have revised it once…
Coming back to: When to suspect the method rather than the sample Replied, post #130 · Analytics › Method validation · 25 Dec 2024 · 1 like Robustness: the method gives consistent results when minor parameters vary. Tested by deliberately varying pH, temperature, flow rate, and mobile phase composition…
Journal club: SURMOUNT-1, read without the press release Replied, post #19 · Evidence › Journal club · 26 Nov 2024 · 0 likes I came in to disagree and I am leaving without a disagreement.
EMA product information as a primary source — does this still hold? Replied, post #43 · Regional › European Union · 16 Nov 2024 · 18 likes A definition problem is doing most of the work in this EMA product information discussion. Once the term is pinned down I suspect the disagreement mostly goes away and…
Here for the analytics and not much else — one year on Replied, post #4 · Lounge › Introductions · 7 Nov 2024 · 28 likes Welcome. The short version of the culture: be specific, date everything, and say when you are guessing. That is genuinely the whole of it. One of those cases where…
Time to steady state after a dose increase Replied, post #160 · Pharmacology › Pharmacokinetics · 6 Nov 2024 · 0 likes Fasting requirement for oral semaglutide: food and large fluid volumes reduce absorption. The fasting window (30 minutes before and 30 minutes after) is designed to…
Time to steady state after a dose increase Replied, post #18 · Pharmacology › Pharmacokinetics · 2 Nov 2024 · 24 likes A pharmacokinetic model fitted to trial data describes the population studied. Applying it to somebody outside the enrolled range is an extrapolation, and the model…
Second pass at: Food noise reducing and the disorientation that can follow Replied, post #6 · Wellbeing › Mental health · 26 Sep 2024 · 6 likes Where a member is finding this hard, the useful reply is usually a question rather than an answer, and this subcategory does that well.
What a stability-indicating method is and how you demonstrate one — one year on Replied, post #38 · Analytics › Method validation · 23 Sep 2024 · 0 likes Answering the question post #35 raises rather than the one it answers. Second-hand on stability-indicating method, so weight it accordingly — someone whose method I…
Meeting a protein target on a suppressed appetite — one year on Replied, post #20 · Nutrition & Training › Protein & intake · 21 Sep 2024 · 14 likes Micronutrient adequacy becomes a real question at very low total intake and is much less discussed than protein. I have seen it go both ways, which is why I hedge.
[2026 update] People with a low starting BMI: where the evidence stops Replied, post #21 · Clinical › Special populations · 7 Sep 2024 · 24 likes Dedicated trials in under-studied populations are the only real remedy and several are ongoing, which is worth saying rather than speculating.
Blind submission and why it changes minds Replied, post #26 · Sourcing › Independent verification · 31 Jul 2024 · 10 likes Where the blind submission reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.
Splitting a weekly dose in two: the pharmacokinetic argument against — the long version Replied, post #69 · Practice › Dosing & titration · 8 Jul 2024 · 25 likes Post #66 is the version of this I will quote in future. One addition. Holding a dose indefinitely: the trials did not study indefinite holding at a non-maximum dose.…